Walter and Eliza Hall Institute researchers have genetically engineered a new laboratory model that enables accurate testing of anti-cancer drugs by mimicking the complexity of human cancers.
Using this advanced model, researchers will be able to discover the safest and most effective ways to use promising drugs called MCL-1 inhibitors in the clinic.
The work was led by PhD student Ms Margs Brennan, Dr Gemma Kelly and Associate Professor Marco Herold, and has been published in the journal Blood.
At a glance
- Researchers have genetically engineered a laboratory model for testing the effectiveness of new anti-cancer drugs called MCL-1 inhibitors.
- The model is the best available for preclinical testing of MCL-1 inhibitors and will help to identify the right patients for these drugs.
- MCL-1 inhibitors work by targeting a protein essential for the sustained growth of many blood cancers, as well as solid tumours including breast cancers and melanoma.